Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732309) titled 'A Study of ATG-201 in Adult Participants With Autoimmune Diseases' on July 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Antengene Biologics Limited
Condition:
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)
Sjogren's Disease
Intervention:
Drug: ATG-201
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 1, 2026
Target Sample Size: 149
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07732309...